Clinical drug investigation
March 1, 2022
Anton L. V. Avanceña, J. Kahn, Elliot Marseille
19 citations
Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to psychotherapy with placebo. This study estimates potential costs, health benefits, and net savings of expanding access to MDMA-AT to eligible US patients with chronic and severe PTSD. Using a...
PLoS One
February 25, 2022
Elliot Marseille, Jennifer Mitchell, James G. Kahn
49 citations
Background Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study updates the cost-effectiveness analysis of this novel therapy using data from a new phase 3...
Journal of Humanistic Psychology
February 10, 2022
Terence H. W. Ching, Monnica T. Williams, Sara Reed et al.
10 citations
MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was...
Drug and Alcohol Dependence
February 1, 2022
Christopher R. Nicholas, Julie B. Wang, Allison R. Coker et al.
67 citations
Background Post-traumatic stress disorder (PTSD) is commonly associated with alcohol and substance use disorders (ASUD). A randomized, placebo-controlled, phase 3 trial demonstrated the safety and efficacy of MDMA-assisted therapy (MDMA-AT) for the treatment of severe PTSD. This analysis explores patterns of alcohol and substance use in patients receiving MDMA-AT compared to placebo plus...
Frontiers in Psychiatry
2022
S Parker Singleton, Julie B. Wang, Michael C Mithoefer et al.
36 citations
3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to facilitate the therapeutic process, in part, by decreasing fear response during fear memory processing while increasing extinction learning. The acute administration of MDMA in healthy controls modifies recruitment...
Alcoholism & Drug Abuse Weekly
October 29, 2021
Alison Knopf
Most patients with substance use disorder (SUD) also have anxiety, and many have post‐traumatic stress disorder (PTSD), using drugs or alcohol to self‐medicate (although not effectively). What happens with PTSD occurs in the amygdala, explained George Koob, Ph.D., director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), in an interview with ADAW last week. The emotional part...
The Journal of Clinical Pharmacology
October 28, 2021
K W Smith, Dakota Sicignano, Adrían V. Hernández et al.
136 citations
Abstract This article discusses current literature on the use of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD). MDMA, the intended active ingredient in illicit Ecstasy or Molly products, is a psychedelic that causes an elevated mood, feeling of bonding, and increased energy. In MDMA‐assisted psychotherapy, patients are...
Cell Reports Medicine
August 1, 2021
John H. Krystal, Benjamin Kelmendi, Ismene L. Petrakis
13 citations
A promising new Phase III study of MDMA plus psychotherapy for PTSD treatment by Mitchell and colleagues that appeared in Nature Medicine raises important new questions about the biology and optimal treatment of this disorder.
The Brown University Psychopharmacology Update
August 1, 2021
Adding 3,4‐methylenedioxymethamphetamine (MDMA) to manualized therapy for post‐traumatic stress disorder (PTSD) resulted in significant symptom improvement and reduced functional impairment relative to placebo in a Phase 3 trial. The researchers observed no increase in adverse events from use of MDMA, including no increase in suicidality. Study results were published online May 10 in Nature...
Journal of Traumatic Stress
August 1, 2021
Linnae Ponté, Lisa Jerome, Scott Hamilton et al.
42 citations
Expression of concern
Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased attention on sleep in clinical PTSD research, SDs remain difficult to treat. In Phase 2 trials, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been shown to greatly improve PTSD symptoms. We hypothesized that MDMA-assisted...